Skip to main content
Fig. 1 | Journal of Medical Case Reports

Fig. 1

From: Management of a human immunodeficiency virus case with discordant antiviral drug resistance profiles in cerebrospinal fluid compared with plasma: a case report

Fig. 1

Resistance mutation development, antiretroviral therapy, human immunodeficiency virus-1 RNA viral load, and cluster of differentiation 4 cell count over time. a human immunodeficiency virus resistance mutation patterns are shown (red background), susceptible (green background), cerebrospinal fluid findings (yellow background), and time in months from the initial presentation (T = 0). b Plasma and cerebrospinal human immunodeficiency virus-1 RNA viral load and cluster of differentiation 4 cell count are shown over time. Antiretroviral therapy was commenced with a three-drug combination therapy including two nucleoside(tide) reverse-transcriptase inhibitors (lamivudine, zidovudine), and the non-nucleoside reverse transcriptase EFV 60 months after initial presentation. The non-nucleoside reverse transcriptase was discontinued and a protease inhibitor was added (month 75). Therapy was intensified to a four-drug regimen (month 169) with the inclusion of the INI raltegravir, and later substituted by the more potent dolutegravir (month 227). The different nucleoside(tide) reverse-transcriptase inhibitors used for treatment included lamivudine, zidovudine, tenofovir, abacavir, and emtricitabine). Protease inhibitors used were nelfinavir, lopinavir/ritonavir, atazanavir, and darunavir

Back to article page